{"entity":{"id":"idea-reg-orphan-designation-reciprocity","kind":"idea","name":"Automatic reciprocity of orphan and rare-paediatric designations between regulators","aka":[],"tldr":"A rare cancer drug designated 'orphan' in the US must reapply in Europe, Japan and elsewhere. Recognising each other's decisions would save small companies months.","summary":"Orphan designation (FDA, EMA, MHLW, others) grants fee waivers, protocol assistance and exclusivity, and is applied for separately with different prevalence thresholds and evidence formats. FDA and EMA offer a common application form but decide independently. The proposal is reciprocal recognition: a designation from one stringent regulator is accepted by partners on notification, with local prevalence data required only where the condition's epidemiology plausibly differs.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Regulatory divergence between regions): FDA Oncology Center of Excellence, Project Orbis","url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-regulatory-fragmentation","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Reciprocity increases the number of rare-cancer programmes holding designations in all major regions by at least 30% and shortens time to designation in the second region from months to weeks.","rationale":"Designation is largely a prevalence calculation; rare cancers are rare everywhere. The administrative burden falls disproportionately on small biotechs and academic sponsors, which run most rare-cancer programmes.","test":"Pilot reciprocity for oncology designations between FDA, EMA and MHRA for two years; count programmes designated in all three and time to second designation before and after.","maturity":"speculative","actor":"regulator","cost":"small","horizonYears":2},"route":"/ideas/idea-reg-orphan-designation-reciprocity/","neighbours":{"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"}],"roadmap":[{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/"}]}}